KINETICS OF WT1 OVER-EXPRESSION IN ACUTE MYELOID LEUKEMIA PATIENTS WHO RECEIVED STANDARD CHEMOTHERAPY OR UNDERWENT ALLOGENEIC STEM CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Eisa N. 06/09/16; 134568; PB1668
Dr. Noha Eisa
Contributions
Contributions
Abstract
Abstract: PB1668
Type: Publication Only
Background
Wilms' tumor 1 (WT1) gene expression is well-known pan leukemia marker which overexpressed in more than 90% of newly diagnosed acute myeloid leukemia patients. However, the clinical utility of WT1 monitoring has been somewhat controversial.
Aims
The aim of this study is to compare WT1 transcript level kinetic changes in patients with AML either received standard chemotherapy (Arm A) or underwent allogeneic stem cell transplantation (Arm B).
Methods
Peripheral blood samples collected from 26 patients diagnosed with AML at initial diagnosis. Further samples collected from 9 patient who received standard chemotherapy (Arm A) at post-induction and post-intensification time points. Further samples collected from 8 patients who underwent allogeneic stem cell transplantation (Arm B) before conditioning, at day 30 and at day 100. The remaining 9 patients were not included in the analysis due to either early death or a negative WT1 at diagnosis. Quantitative RT-PCR detection of WT1 gene transcript level using Ipsogen WT1 profile Quant was performed on peripheral blood samples in both arms at the different time points mentioned before.
Results
We observed significant difference in the median values of WT1 transcript level at the 3 time points for patients with Arm A (P value 0.011) while for allogeneic arm B the median values were nearly the same at the 3 time points (P value 0.687). We found that WT1 level post-induction correlates with morphologic response (P value: 0.04). The median values for WT1 level were more for relapsed rather than non-relapsed cases in both arms at the 3 time points, but this difference was statistically insignificant except at D100 in arm B (P-value 0.046) and about to be significant at post-intensification (P value was 0.064) in arm A.
Conclusion
We identified a positive correlation between WT1 transcript level and morphological response. Therefore, elevation or rising WT1 transcript levels after intensifications or beyond day 100 post-transplant may be a marker of impending relapse that if validated in larger studies, may warrant either close observation or pre-emptive intervention. Although our results are poorly reaching the level of significance, probably due to the small sample size, WT1 transcript level showed dynamic changes with treatment and may be a marker for relapse. We recommend further studies with larger number of patients in different centers to confirm these results.
Session topic: E-poster
Keyword(s): AML, Stem cell transplant, WT1
Type: Publication Only
Background
Wilms' tumor 1 (WT1) gene expression is well-known pan leukemia marker which overexpressed in more than 90% of newly diagnosed acute myeloid leukemia patients. However, the clinical utility of WT1 monitoring has been somewhat controversial.
Aims
The aim of this study is to compare WT1 transcript level kinetic changes in patients with AML either received standard chemotherapy (Arm A) or underwent allogeneic stem cell transplantation (Arm B).
Methods
Peripheral blood samples collected from 26 patients diagnosed with AML at initial diagnosis. Further samples collected from 9 patient who received standard chemotherapy (Arm A) at post-induction and post-intensification time points. Further samples collected from 8 patients who underwent allogeneic stem cell transplantation (Arm B) before conditioning, at day 30 and at day 100. The remaining 9 patients were not included in the analysis due to either early death or a negative WT1 at diagnosis. Quantitative RT-PCR detection of WT1 gene transcript level using Ipsogen WT1 profile Quant was performed on peripheral blood samples in both arms at the different time points mentioned before.
Results
We observed significant difference in the median values of WT1 transcript level at the 3 time points for patients with Arm A (P value 0.011) while for allogeneic arm B the median values were nearly the same at the 3 time points (P value 0.687). We found that WT1 level post-induction correlates with morphologic response (P value: 0.04). The median values for WT1 level were more for relapsed rather than non-relapsed cases in both arms at the 3 time points, but this difference was statistically insignificant except at D100 in arm B (P-value 0.046) and about to be significant at post-intensification (P value was 0.064) in arm A.
Conclusion
We identified a positive correlation between WT1 transcript level and morphological response. Therefore, elevation or rising WT1 transcript levels after intensifications or beyond day 100 post-transplant may be a marker of impending relapse that if validated in larger studies, may warrant either close observation or pre-emptive intervention. Although our results are poorly reaching the level of significance, probably due to the small sample size, WT1 transcript level showed dynamic changes with treatment and may be a marker for relapse. We recommend further studies with larger number of patients in different centers to confirm these results.
Session topic: E-poster
Keyword(s): AML, Stem cell transplant, WT1
Abstract: PB1668
Type: Publication Only
Background
Wilms' tumor 1 (WT1) gene expression is well-known pan leukemia marker which overexpressed in more than 90% of newly diagnosed acute myeloid leukemia patients. However, the clinical utility of WT1 monitoring has been somewhat controversial.
Aims
The aim of this study is to compare WT1 transcript level kinetic changes in patients with AML either received standard chemotherapy (Arm A) or underwent allogeneic stem cell transplantation (Arm B).
Methods
Peripheral blood samples collected from 26 patients diagnosed with AML at initial diagnosis. Further samples collected from 9 patient who received standard chemotherapy (Arm A) at post-induction and post-intensification time points. Further samples collected from 8 patients who underwent allogeneic stem cell transplantation (Arm B) before conditioning, at day 30 and at day 100. The remaining 9 patients were not included in the analysis due to either early death or a negative WT1 at diagnosis. Quantitative RT-PCR detection of WT1 gene transcript level using Ipsogen WT1 profile Quant was performed on peripheral blood samples in both arms at the different time points mentioned before.
Results
We observed significant difference in the median values of WT1 transcript level at the 3 time points for patients with Arm A (P value 0.011) while for allogeneic arm B the median values were nearly the same at the 3 time points (P value 0.687). We found that WT1 level post-induction correlates with morphologic response (P value: 0.04). The median values for WT1 level were more for relapsed rather than non-relapsed cases in both arms at the 3 time points, but this difference was statistically insignificant except at D100 in arm B (P-value 0.046) and about to be significant at post-intensification (P value was 0.064) in arm A.
Conclusion
We identified a positive correlation between WT1 transcript level and morphological response. Therefore, elevation or rising WT1 transcript levels after intensifications or beyond day 100 post-transplant may be a marker of impending relapse that if validated in larger studies, may warrant either close observation or pre-emptive intervention. Although our results are poorly reaching the level of significance, probably due to the small sample size, WT1 transcript level showed dynamic changes with treatment and may be a marker for relapse. We recommend further studies with larger number of patients in different centers to confirm these results.
Session topic: E-poster
Keyword(s): AML, Stem cell transplant, WT1
Type: Publication Only
Background
Wilms' tumor 1 (WT1) gene expression is well-known pan leukemia marker which overexpressed in more than 90% of newly diagnosed acute myeloid leukemia patients. However, the clinical utility of WT1 monitoring has been somewhat controversial.
Aims
The aim of this study is to compare WT1 transcript level kinetic changes in patients with AML either received standard chemotherapy (Arm A) or underwent allogeneic stem cell transplantation (Arm B).
Methods
Peripheral blood samples collected from 26 patients diagnosed with AML at initial diagnosis. Further samples collected from 9 patient who received standard chemotherapy (Arm A) at post-induction and post-intensification time points. Further samples collected from 8 patients who underwent allogeneic stem cell transplantation (Arm B) before conditioning, at day 30 and at day 100. The remaining 9 patients were not included in the analysis due to either early death or a negative WT1 at diagnosis. Quantitative RT-PCR detection of WT1 gene transcript level using Ipsogen WT1 profile Quant was performed on peripheral blood samples in both arms at the different time points mentioned before.
Results
We observed significant difference in the median values of WT1 transcript level at the 3 time points for patients with Arm A (P value 0.011) while for allogeneic arm B the median values were nearly the same at the 3 time points (P value 0.687). We found that WT1 level post-induction correlates with morphologic response (P value: 0.04). The median values for WT1 level were more for relapsed rather than non-relapsed cases in both arms at the 3 time points, but this difference was statistically insignificant except at D100 in arm B (P-value 0.046) and about to be significant at post-intensification (P value was 0.064) in arm A.
Conclusion
We identified a positive correlation between WT1 transcript level and morphological response. Therefore, elevation or rising WT1 transcript levels after intensifications or beyond day 100 post-transplant may be a marker of impending relapse that if validated in larger studies, may warrant either close observation or pre-emptive intervention. Although our results are poorly reaching the level of significance, probably due to the small sample size, WT1 transcript level showed dynamic changes with treatment and may be a marker for relapse. We recommend further studies with larger number of patients in different centers to confirm these results.
Session topic: E-poster
Keyword(s): AML, Stem cell transplant, WT1
{{ help_message }}
{{filter}}